Clinical TrialMay 22, 2026, 07:02 AM
BioLineRx & Hemispherian Highlight GLIX1 Data at ASCO 2026
AI Summary
BioLineRx Ltd. and Hemispherian AS announced that new data on GLIX1, their investigational oral small molecule, will be featured at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting. The data highlights GLIX1's novel mechanism of action, which involves restoring TET2 activity to induce tumor-selective DNA strand breaks, and its strong preclinical antitumor activity in glioblastoma (GBM) and other cancers. A first-in-human Phase 1/2a clinical trial for GLIX1 in GBM was initiated in March, supported by these compelling preclinical findings and observed synergistic effects with PARP inhibitors.
Key Highlights
- BioLineRx and Hemispherian AS highlighted new GLIX1 data at the ASCO 2026 Annual Meeting.
- GLIX1 is a first-in-class oral molecule targeting the DNA damage response by restoring TET2 activity.
- A first-in-human Phase 1/2a clinical trial for GLIX1 in glioblastoma (GBM) was initiated in March.
- Preclinical studies showed GLIX1 increased TET2 activity and demonstrated strong antitumor activity in GBM models.
- GLIX1 efficiently penetrated the brain in animal models, reaching 68-85% of plasma levels.
- Safety studies indicated GLIX1 was well-tolerated at high doses in rats (2000mg/kg) and dogs (1000mg/kg).
- Preclinical in vitro studies showed synergistic antitumor activity when GLIX1 was combined with PARP inhibitors.
Price Impact
More from BLRX